What Aveanna Healthcare (AVAH) Said on Its Q3 Earnings Call

Aveanna Healthcare (AVAH) reported Q3 revenue growth of 15.6% to $72.1M in Home Health and Hospice, and 9.1% to $49.2M in Medical Solutions. CEO Shaner cautioned that 20-25% growth is unsustainable. The company secured $30M in California funding for rate increases, aiming for permanency. Aveanna reconfirmed long-term growth targets and plans to focus acquisitions on Home Health and Hospice. It reported $492M in liquidity and $1.52B in variable-rate debt, all hedged through 2029.

Original reporting
Published Nov 12, 2026, 5:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 5:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What Aveanna Healthcare (AVAH) Said on Its Q3 Earnings Call — source image
Decision brief

The 30-second read

$AVAHBullishMed
01

Why it matters

The earnings beat and guidance suggest continued operational strength, but reliance on state rate increases introduces execution risk.

02

Market read

First disclosure of Q3 financials for AVAH offers fresh data for traders; modest upside potential if guidance is viewed positively.

03

What to watch

Potential staffing shortages and the uncertainty around the duration of the temporary rate increase could constrain future earnings.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Aveanna Healthcare (AVAH) disclosed Q3 results, highlighted revenue growth across segments, and provided guidance for Q4 EBITDA and leverage reduction.

Company-level read

Ticker impact

$AVAHBullishHigh confidence
Context

Q3 earnings release with revenue, margin, cash flow numbers and guidance for Q4 EBITDA and leverage targets.

Expected impact

potential modest upside as investors price in better-than-expected revenue and margin trends

Evidence & confidence

First report of Q3 results provides fresh data; guidance is in line with expectations but highlights cash generation and leverage reduction, which could support a slight price rise.

Market effects

Home health and hospice providers may see increased investor interest as AVAH reports strong margin expansion.

California rate increase could set a precedent for other states, affecting regional home‑care providers.

Limited; primarily impacts U.S. home‑health sector.

Counterpoint

If the rate increase in California proves temporary, the growth outlook may be overstated, leading to downside risk.

Key entities

  • Shaner

    CEO providing earnings commentary and guidance.

  • Buckhalter

    CFO discussing debt hedging and leverage targets.

Related articles

$AVAHHighAI 8/10

Aveanna Healthcare Earnings Call Signals Broader Growth, Higher Guidance

Aveanna Healthcare (AVAH) reported Q3 revenue of $695.5M, up 11.8%, and adjusted EBITDA of $100.1M, up 25%. All segments grew, with Home Health and Hospice up 15.6%, Private Duty Services up 11.6%, and Medical Solutions up 9.1%. The company raised 2026 guidance to revenue above $2.695B and adjusted EBITDA above $374M, citing growth in preferred payers and state rate enhancements. Management highlighted caregiver shortages and California rate uncertainty as risks.

$AVAHHigh

Raymond James reiterates Strong Buy on Aveanna stock after beat

Raymond James reiterated a Strong Buy rating and $15.00 price target for Aveanna Healthcare (AVAH) after its Q3 2026 results beat estimates. AVAH reported adjusted EBITDA of $100.1M, 7.5% above consensus, and raised its 2026 EBITDA guidance to at least $374M. The stock trades at $13.09, with 13% upside to the target. RBC Capital increased its price target to $16.00, citing positive market positioning.

$AVAHHighAI 8/10

Aveanna Healthcare shares fall 6% despite third quarter beat

Aveanna Healthcare (AVAH) reported Q3 earnings of $0.23 per share, beating estimates by $0.02, with revenue of $695.5M, up 11.8% YoY. Despite this, shares fell 6.04% pre-market due to fiscal 2026 guidance that aligned with analyst expectations. The company raised its full-year revenue guidance to over $2.695B and EBITDA guidance to over $374M. All three business segments contributed to revenue growth, and net income rose to $45.5M from $14.1M YoY.